
Leiden University Medical Center will deliver a publishable MRSA PolC-inhibitor structure that reshapes Acurx’s next antibiotic development milestones.
Structural clarity can compress drug-discovery timelines and de-risk optimization—especially in antibiotics, where resistance and limited new classes remain a global threat.
AI reasoning
Structural clarity can compress drug-discovery timelines and de-risk optimization—especially in antibiotics, where resistance and limited new classes remain a global threat.
Curated summary
Acurx Pharmaceuticals announced a scientific partnership with Leiden University Medical Center in the Netherlands to seek the first 3D structure of MRSA PolC bound to DNA and an Acurx inhibitor. The company said the work is designed to accelerate development of its DNA Polymerase IIIC inhibitor antibiotics. Acurx said the project builds on a November 2025 Health-Holland grant and earlier research published in Nature Communications, with the stated goal of systemically active drugs against Gram-positive pathogens that resist current antibiotics.
Supporting evidence
YouTube·WebsEdgeMedicineBroadly Focussed Translational Genetics Research - Leiden University Medical Center, The Netherlands
832 engagements2h ago
YouTube·Leids Universitair Medisch CentrumHypoVax
117 engagements2h ago
YouTube·Leids Universitair Medisch CentrumLUMC Planetaire gezondheid en duurzaamheid in het onderwijs ENG
111 engagements2h ago
YouTube·Civil CouncilFloor van der Does, - Leiden University Medical Center
90 engagements2h ago
YouTube·New to The Street TVAcurx Pharma Partners With Leiden University to Advance Next-Generation Antibiotics
66 engagements2h ago
YouTube·NewsOutAcurx Pharma Advances Antibiotic Program Toward Phase 3 C. diff Trials | NewsOut
2h ago
YouTube·NewsOutAcurx Pharma Reports Positive FDA Meeting for Ibuzatrelvir Phase 3 Program
2h ago
YouTube·WebsEdgeMedicineCenter for Endocrine Tumors Leiden – Leiden University Medical Center
2h ago
Source news
Acurx partners with Leiden University Medical Center to pursue first 3D structure of MRSA PolC bound to DNA and inhibitor
The collaboration targets a structural breakthrough intended to speed development of new antibiotics against resistant Gram-positive pathogens.















